229 related articles for article (PubMed ID: 11812097)
1. Paclitaxel and carboplatin combination chemotherapy in a hemodialysis patient with advanced ovarian cancer.
Watanabe M; Aoki Y; Tomita M; Sato T; Takaki Y; Kato N; Kikuchi M; Kase H; Tanaka K
Gynecol Oncol; 2002 Feb; 84(2):335-8. PubMed ID: 11812097
[TBL] [Abstract][Full Text] [Related]
2. [Pharmacokinetics of paclitaxel and carboplatin in a hemodialysis patient with metastatic urothelial carcinoma--a case report].
Furuya Y; Takihana Y; Araki I; Tanabe N; Takeda M
Gan To Kagaku Ryoho; 2003 Jul; 30(7):1017-20. PubMed ID: 12894722
[TBL] [Abstract][Full Text] [Related]
3. Clinical trial and pharmacokinetic study of combination paclitaxel and carboplatin in patients with epithelial ovarian cancer.
Yamamoto R; Kaneuchi M; Nishiya M; Todo Y; Takeda M; Okamoto K; Negishi H; Sakuragi N; Fujimoto S; Hirano T
Cancer Chemother Pharmacol; 2002 Aug; 50(2):137-42. PubMed ID: 12172979
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetic analysis of carboplatin in patients with cancer who are undergoing hemodialysis.
Oguri T; Shimokata T; Inada M; Ito I; Ando Y; Sasaki Y; Hasegawa Y
Cancer Chemother Pharmacol; 2010 Sep; 66(4):813-7. PubMed ID: 20563583
[TBL] [Abstract][Full Text] [Related]
5. Population pharmacokinetics and pharmacodynamics of paclitaxel and carboplatin in ovarian cancer patients: a study by the European organization for research and treatment of cancer-pharmacology and molecular mechanisms group and new drug development group.
Joerger M; Huitema AD; Richel DJ; Dittrich C; Pavlidis N; Briasoulis E; Vermorken JB; Strocchi E; Martoni A; Sorio R; Sleeboom HP; Izquierdo MA; Jodrell DI; Calvert H; Boddy AV; Hollema H; Féty R; Van der Vijgh WJ; Hempel G; Chatelut E; Karlsson M; Wilkins J; Tranchand B; Schrijvers AH; Twelves C; Beijnen JH; Schellens JH
Clin Cancer Res; 2007 Nov; 13(21):6410-8. PubMed ID: 17975154
[TBL] [Abstract][Full Text] [Related]
6. Paclitaxel/carboplatin as first-line chemotherapy in advanced ovarian cancer: efficacy and adverse effects with special consideration of peripheral neurotoxicity.
Mayerhofer K; Bodner-Adler B; Bodner K; Leodolter S; Kainz C
Anticancer Res; 2000; 20(5C):4047-50. PubMed ID: 11268499
[TBL] [Abstract][Full Text] [Related]
7. Intraperitoneal carboplatin infusion may be a pharmacologically more reasonable route than intravenous administration as a systemic chemotherapy. A comparative pharmacokinetic analysis of platinum using a new mathematical model after intraperitoneal vs. intravenous infusion of carboplatin--a Sankai Gynecology Study Group (SGSG) study.
Miyagi Y; Fujiwara K; Kigawa J; Itamochi H; Nagao S; Aotani E; Terakawa N; Kohno I;
Gynecol Oncol; 2005 Dec; 99(3):591-6. PubMed ID: 16095677
[TBL] [Abstract][Full Text] [Related]
8. Carboplatin and paclitaxel in patients with advanced ovarian cancer: a dose-finding study.
ten Bokkel Huinink W; Veenhof C; Huizing M; Rodenhuis S; Helmerhorst T; Dubbelman R; Dalesio O; Beijnen J; Winograd B
Semin Oncol; 1997 Feb; 24(1 Suppl 2):S2-31-S2-33. PubMed ID: 9045333
[TBL] [Abstract][Full Text] [Related]
9. Is age a barrier to the aggressive treatment of ovarian cancer with paclitaxel and carboplatin?
Higgins RV; Naumann RW; Gardner J; Hall JB
Gynecol Oncol; 1999 Dec; 75(3):464-7. PubMed ID: 10600308
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of weekly low-dose paclitaxel and carboplatin treatment for patients with platinum-sensitive relapsed ovarian cancer.
Watanabe Y; Nakai H; Ueda H; Hoshiai H
Gynecol Oncol; 2005 Feb; 96(2):323-9. PubMed ID: 15661216
[TBL] [Abstract][Full Text] [Related]
11. Carboplatin in combination with paclitaxel in advanced ovarian cancer: dose determination and pharmacokinetic and pharmacodynamic interactions.
Calvert AH; Boddy A; Bailey NP; Siddiqui N; Humphreys A; Hughes A; Robson L; Gumbrell L; Thomas H; Chapman F
Semin Oncol; 1995 Oct; 22(5 Suppl 12):91-8; discussion 99-100. PubMed ID: 7481870
[TBL] [Abstract][Full Text] [Related]
12. Phase I study of alternating doublets of topotecan/carboplatin and paclitaxel/carboplatin in patients with newly diagnosed, advanced ovarian cancer.
Gordon AN; Hancock KC; Matthews CM; Messing M; Stringer CA; Doherty MG; Teneriello M
Gynecol Oncol; 2002 Apr; 85(1):129-35. PubMed ID: 11925132
[TBL] [Abstract][Full Text] [Related]
13. Phase II study of sequential doublets: topotecan and carboplatin, followed by paclitaxel and carboplatin, in patients with newly diagnosed advanced ovarian cancer.
Gordon AN; Asmar L; Messing MJ; Street DG; Pippitt CH; Bailey CL; Savage J; Young JA
Gynecol Oncol; 2004 Aug; 94(2):533-9. PubMed ID: 15297200
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics of paclitaxel and carboplatin in combination.
Kearns CM; Belani CP; Erkmen K; Zuhowski M; Hiponia D; Zacharski D; Engstrom C; Ramanathan R; Trenn MR; Aisner J
Semin Oncol; 1995 Oct; 22(5 Suppl 12):1-4; discussion 5-7. PubMed ID: 7481850
[TBL] [Abstract][Full Text] [Related]
15. Topotecan compared with no therapy after response to surgery and carboplatin/paclitaxel in patients with ovarian cancer: Multicenter Italian Trials in Ovarian Cancer (MITO-1) randomized study.
De Placido S; Scambia G; Di Vagno G; Naglieri E; Lombardi AV; Biamonte R; Marinaccio M; Cartenì G; Manzione L; Febbraro A; De Matteis A; Gasparini G; Valerio MR; Danese S; Perrone F; Lauria R; De Laurentiis M; Greggi S; Gallo C; Pignata S
J Clin Oncol; 2004 Jul; 22(13):2635-42. PubMed ID: 15226331
[TBL] [Abstract][Full Text] [Related]
16. A phase I study of intraperitoneal topotecan in combination with intravenous carboplatin and paclitaxel in advanced ovarian cancer.
Bos AM; De Vos FY; de Vries EG; Beijnen JH; Rosing H; Mourits MJ; van der Zee AG; Gietema JA; Willemse PH
Eur J Cancer; 2005 Mar; 41(4):539-48. PubMed ID: 15737558
[TBL] [Abstract][Full Text] [Related]
17. [Pharmacokinetics of carboplatin in a patient under hemodialysis].
Kurata H; Yoshiya N; Ikarashi H; Kaneko T; Kodama S; Tanaka K; Suzuki K; Yoshizawa H; Cho T; Suzuki E
Gan To Kagaku Ryoho; 1994 Mar; 21(4):547-50. PubMed ID: 8129398
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of combined radiation, paclitaxel and carboplatin for locally advanced non-small cell lung carcinoma.
Nguyen NP; Leonardo JM; Karlsson U; Vos P; Bullock L; Thomas P; Lepera P; Ludin A; Chu C; Salehpour M; Jendrasiak G; Sallah S
Anticancer Res; 2002; 22(6B):3429-35. PubMed ID: 12552935
[TBL] [Abstract][Full Text] [Related]
19. First-line chemotherapy with weekly paclitaxel and carboplatin for advanced ovarian cancer: a phase I study.
Sehouli J; Stengel D; Elling D; Ortmann O; Blohmer J; Riess H; Lichtenegger W;
Gynecol Oncol; 2002 May; 85(2):321-6. PubMed ID: 11972395
[TBL] [Abstract][Full Text] [Related]
20. [A case of ovarian cancer with Parkinson's disease treated by combined chemotherapy with paclitaxel and carboplatin followed by surgery].
Furukawa M; Fujiwara H; Urabe S; Egawa M; Fujitoh N; Sakashita T; Date K; Mizunoe T; Ueda K; Urabe T
Gan To Kagaku Ryoho; 2003 Dec; 30(13):2129-32. PubMed ID: 14712777
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]